BARBRA BONSU: Open Payments
NPI 1710384482 · DISTRICT HEIGHTS, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,699 in 90 payments from 18 companies in 2025. Trend: 2023 $470 · 2024 $926 · 2025 $2,699
Food & beverage: $2,579Education: $120
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 26 | $701 |
| GENZYME CORPORATION | 20 | $526 |
| GlaxoSmithKline, LLC. | 11 | $211 |
| ARS Pharmaceuticals Operations, Inc. | 7 | $192 |
| Regeneron Healthcare Solutions, Inc. | 4 | $181 |
| Grifols USA, LLC | 5 | $144 |
| Galderma Laboratories, L.P. | 1 | $118 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $97 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $94 |
| Amgen Inc. | 1 | $93 |
Products named: DUPIXENT, TEZSPIRE, FASENRA, NEFFY, AIRSUPRA, NEMLUVIO, Prolastin-C Liquid, NUCALA.
Industry payments across MD — which companies pay providers there.
